Page last updated: 2024-11-06

gr 117289

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

GR 117289: angiotensin AT1 receptor antagonist; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

zolasartan : A member of the class of 1-benzofurans that is 3-bromo-1-benzofuran which is substituted by a 2-(1H-tetrazol-5-yl)phenyl group at position 2 and by a (2-butyl-5-carboxy-4-chloro-1H-imidazol-1-yl)methyl group at position 5. It is an angiotensin II receptor type 1 (AT1) antagonist and was in clinical trials for the treatment of hypertension (now discontinued). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID72168
CHEMBL ID304639
CHEBI ID149761
SCHEMBL ID489476
MeSH IDM0211099

Synonyms (29)

Synonym
zolasartan
CHEMBL304639
L005720
3-[[3-bromo-2-[2-(2h-tetrazol-5-yl)phenyl]-1-benzofuran-5-yl]methyl]-2-butyl-5-chloroimidazole-4-carboxylic acid
1h-imidazole-5-carboxylic acid, 1-[[3-bromo-2-[2-(2h-tetrazol-5-yl)phenyl]-5-benzofuranyl]methyl]-2-butyl-4-chloro-
1-({3-bromo-2-[2-(1h-tetrazol-5-yl)phenyl]-1-benzofuran-5-yl}methyl)-2-butyl-4-chloro-1h-imidazole-5-carboxylic acid
1-((3-bromo-2-(o-1h-tetrazol-5-ylphenyl)-5-benzofuranyl)methyl)-2-butyl-4-chloroimidazole-5-carboxylic acid
145781-32-4
gr117289
gr 117289
gr-117289c
CHEBI:149761
gr-117289
zolasartanum
gr117289c
gr 117289c
gr-117289x
zolasartan [inn:ban]
6na6uhb9sw ,
1-((3-bromo-2-(2-(1h-tetrazol-5-yl)phenyl)-5-benzofuranyl)methyl)-2-butyl-4-chloro-1h-imidazole-5-carboxylic acid
gr 117289x
gr117289x
unii-6na6uhb9sw
zolasartan [inn]
SCHEMBL489476
DTXSID70163156
gr 117289;gr 117289c;gr 117289x
Q27265192
AKOS040749856

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Using GR117289, a compound with moderate bioavailability (20%) in man as a lead, we pursued a strategy aimed at enhancing bioavailability."( Bromobenzofuran-based non-peptide antagonists of angiotensin II: GR138950, a potent antihypertensive agent with high oral bioavailability.
Dowle, MD; Hobson, JE; Jack, TI; Judd, DB; Middlemiss, D; Panchal, TA; Pass, M; Ross, BC; Scopes, DI; Tranquillini, E, 1994
)
0.29

Dosage Studied

ExcerptRelevanceReference
" Systemic or oral administration of GR1 17289 (3 mg kg-1)inhibited the pressor responses produced by All, resulting in parallel, rightward displacements of All dose-response curves."( Cardiovascular effects of GR117289, a novel angiotensin AT1 receptor antagonist.
Drew, GM; Gardner, CJ; Hilditch, A; Hunt, AA; Middlemiss, D; Polley, J; Robertson, MJ; Ross, BC; Travers, A; Twissell, DJ, 1994
)
0.29
" In IMA rings incubated with 1 or 10 nmol/L GR117289C, contractile responses to AII were attenuated in a concentration-related manner, whereas the dose-response curve did not shift to the right when higher doses of AII were administered, suggesting that the AT1 receptor blockade was noncompetitive in nature."( Inhibition of vasoconstriction by angiotensin receptor antagonist GR117289C in arterial grafts.
Floten, HS; Furnary, AP; He, GW; Liu, MH; Yim, AP, 2000
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
angiotensin receptor antagonistA hormone antagonist that blocks angiotensin receptors.
antihypertensive agentAny drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (7)

ClassDescription
tetrazolesAn azole in which the five-membered heterocyclic aromatic skeleton contains four N atoms and one C atom.
imidazolyl carboxylic acidAny member of the class of imidazoles in which the imidazole ring is substituted by one (or more) carboxy group(s).
1-benzofuransA member of the class of benzofurans consisting of a 1-benzofuran skeleton and its substituted derivatives thereof.
organochlorine compoundAn organochlorine compound is a compound containing at least one carbon-chlorine bond.
organobromine compoundA compound containing at least one carbon-bromine bond.
monocarboxylic acidAn oxoacid containing a single carboxy group.
biarylAn organic aromatic compound whose structure contains two aromatic rings or ring systems, joined to each other by a single bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Type-1 angiotensin II receptorHomo sapiens (human)Ki0.00200.00020.18374.7000AID568891
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (28)

Processvia Protein(s)Taxonomy
regulation of cell growthType-1 angiotensin II receptorHomo sapiens (human)
kidney developmentType-1 angiotensin II receptorHomo sapiens (human)
renin-angiotensin regulation of aldosterone productionType-1 angiotensin II receptorHomo sapiens (human)
maintenance of blood vessel diameter homeostasis by renin-angiotensinType-1 angiotensin II receptorHomo sapiens (human)
regulation of systemic arterial blood pressure by renin-angiotensinType-1 angiotensin II receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayType-1 angiotensin II receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayType-1 angiotensin II receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationType-1 angiotensin II receptorHomo sapiens (human)
Rho protein signal transductionType-1 angiotensin II receptorHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationType-1 angiotensin II receptorHomo sapiens (human)
regulation of vasoconstrictionType-1 angiotensin II receptorHomo sapiens (human)
calcium-mediated signalingType-1 angiotensin II receptorHomo sapiens (human)
positive regulation of phospholipase A2 activityType-1 angiotensin II receptorHomo sapiens (human)
low-density lipoprotein particle remodelingType-1 angiotensin II receptorHomo sapiens (human)
regulation of renal sodium excretionType-1 angiotensin II receptorHomo sapiens (human)
angiotensin-activated signaling pathwayType-1 angiotensin II receptorHomo sapiens (human)
regulation of cell population proliferationType-1 angiotensin II receptorHomo sapiens (human)
symbiont entry into host cellType-1 angiotensin II receptorHomo sapiens (human)
regulation of inflammatory responseType-1 angiotensin II receptorHomo sapiens (human)
positive regulation of inflammatory responseType-1 angiotensin II receptorHomo sapiens (human)
positive regulation of protein metabolic processType-1 angiotensin II receptorHomo sapiens (human)
cell chemotaxisType-1 angiotensin II receptorHomo sapiens (human)
phospholipase C-activating angiotensin-activated signaling pathwayType-1 angiotensin II receptorHomo sapiens (human)
blood vessel diameter maintenanceType-1 angiotensin II receptorHomo sapiens (human)
positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesisType-1 angiotensin II receptorHomo sapiens (human)
positive regulation of CoA-transferase activityType-1 angiotensin II receptorHomo sapiens (human)
positive regulation of reactive oxygen species metabolic processType-1 angiotensin II receptorHomo sapiens (human)
inflammatory responseType-1 angiotensin II receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
angiotensin type I receptor activityType-1 angiotensin II receptorHomo sapiens (human)
angiotensin type II receptor activityType-1 angiotensin II receptorHomo sapiens (human)
protein bindingType-1 angiotensin II receptorHomo sapiens (human)
bradykinin receptor bindingType-1 angiotensin II receptorHomo sapiens (human)
protein heterodimerization activityType-1 angiotensin II receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
plasma membraneType-1 angiotensin II receptorHomo sapiens (human)
membraneType-1 angiotensin II receptorHomo sapiens (human)
plasma membraneType-1 angiotensin II receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID568893Antihypertensive activity in left renal artery-ligated hypertensive rat model assessed as reduction of diastolic blood pressure at 1 to 10 mg/kg, po for 6 days2010Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24
Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
AID568895Cardiotoxicity in left renal artery-ligated hypertensive rat model assessed as reduction of heart rate at 0.3 to 3 mg/kg, administered intra-arterially for 6 days2010Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24
Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
AID18176Oral bioavailability in rat1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
AID568891Displacement of [3H]-angiotensin 2 from angiotensin AT1 receptor2010Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24
Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
AID167537Compound was tested for its antagonistic activity against angiotensin II-induced contractions in rabbit aorta1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
AID10303Half-life in plasma of dog at dose of 3-10 mgkg1994Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19
Bromobenzofuran-based non-peptide antagonists of angiotensin II: GR138950, a potent antihypertensive agent with high oral bioavailability.
AID11089The compound was tested for volume of distribution in rat at dose of 3-10 mgkg1994Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19
Bromobenzofuran-based non-peptide antagonists of angiotensin II: GR138950, a potent antihypertensive agent with high oral bioavailability.
AID568892Antihypertensive activity in left renal artery-ligated hypertensive rat model assessed as reduction of diastolic blood pressure at 0.3 to 3 mg/kg, administered intra-arterially for 6 days2010Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24
Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
AID568894Cardiotoxicity in left renal artery-ligated hypertensive rat model assessed as reduction of heart rate at 1 to 10 mg/kg, po for 6 days2010Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24
Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
AID9544The compound was tested for plasma clearance in dog at dose of 3-10 mgkg1994Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19
Bromobenzofuran-based non-peptide antagonists of angiotensin II: GR138950, a potent antihypertensive agent with high oral bioavailability.
AID9502Bioavailability in dog (dose 3-10 mg/kg)1994Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19
Bromobenzofuran-based non-peptide antagonists of angiotensin II: GR138950, a potent antihypertensive agent with high oral bioavailability.
AID9889The compound was tested for volume of distribution in dog at dose of 3-10 mgkg1994Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19
Bromobenzofuran-based non-peptide antagonists of angiotensin II: GR138950, a potent antihypertensive agent with high oral bioavailability.
AID37991In vitro antagonistic potency against Angiotensin II receptor, type 1 in rat liver using [125I]-Sar1-Ile8-Ang II as radioligand1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
AID12694Half-life in plasma of rat at dose of 3-10 mgkg1994Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19
Bromobenzofuran-based non-peptide antagonists of angiotensin II: GR138950, a potent antihypertensive agent with high oral bioavailability.
AID13458The compound was tested for plasma clearance in rat at dose of 3-10 mgkg1994Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19
Bromobenzofuran-based non-peptide antagonists of angiotensin II: GR138950, a potent antihypertensive agent with high oral bioavailability.
AID10365Bioavailability in rat (dose 3-10 mg/kg)1994Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19
Bromobenzofuran-based non-peptide antagonists of angiotensin II: GR138950, a potent antihypertensive agent with high oral bioavailability.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's15 (83.33)18.2507
2000's2 (11.11)29.6817
2010's1 (5.56)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.17

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.17 (24.57)
Research Supply Index3.00 (2.92)
Research Growth Index4.17 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.17)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (5.56%)5.53%
Reviews2 (11.11%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]